Combining nanoscale magnetic nimodipine liposomes with magnetic resonance image for Parkinson's disease targeting therapy

Nanomedicine (Lond). 2017 Feb;12(3):237-253. doi: 10.2217/nnm-2016-0267. Epub 2017 Jan 17.

Abstract

Aim: To enhance drug targeting and blood-brain barrier penetration for Parkinson's disease (PD), a novel nanoscale magnetic nimodipine (NMD) delivery system was designed and prepared.

Materials & methods: The PD rats were established and treated with free NMD or Fe3O4-modified NMD liposomes (Fe3O4-NMD-lips). Then, factional anisotropy values were measured by MRI to evaluate therapy efficacy.

Results: Fe3O4-NMD-lips showed the best neuroprotective effect, and the NMD concentration of lesions was 2.5-fold higher in Fe3O4-NMD-lips group than that of free NMD group.

Conclusion: These results demonstrated that the magnetic drug system had a great potential to cross the blood-brain barrier and provided a noninvasive and effective therapeutic strategy for PD.

Keywords: Parkinson's disease; blood–brain barrier; magnetic resonance imaging; nanoscale magnetic liposomes; nimodipine.

MeSH terms

  • Animals
  • Blood-Brain Barrier / metabolism
  • Drug Delivery Systems
  • Drug Liberation
  • Drug Stability
  • Humans
  • Liposomes / chemistry*
  • Magnetic Resonance Imaging
  • Magnetite Nanoparticles / chemistry*
  • Molecular Targeted Therapy
  • Neuroprotective Agents / administration & dosage*
  • Neuroprotective Agents / adverse effects
  • Neuroprotective Agents / chemistry
  • Nimodipine / administration & dosage*
  • Nimodipine / adverse effects
  • Nimodipine / chemistry
  • Parkinson Disease / diagnostic imaging
  • Parkinson Disease / drug therapy*
  • Rats
  • Tissue Distribution

Substances

  • Liposomes
  • Magnetite Nanoparticles
  • Neuroprotective Agents
  • Nimodipine